APLT
Applied Therapeutics Inc.
$0.48
+$0.04(+9.45%)
40
Overall
--
Value
40
Tech
--
Quality
Market Cap
$61.54M
Volume
1.41M
52W Range
$0.30 - $10.62
Target Price
$3.17
Order:
Income Statement
| Metric | Trend | Chart | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| Total Revenue | -- | -- | -- | -- | $10.0M | $455.0K | ||
| Total Revenue | -- | -- | -- | -- | $10.0M | $455.0K | ||
| GROSS PROFIT | ||||||||
| Gross Profit | -- | -- | -- | -- | $10.0M | $455.0K | ||
| OPERATING EXPENSES | ||||||||
| Operating Expenses | $45.6M | $94.5M | $105.6M | $83.0M | $74.5M | $104.8M | ||
| Research & Development | $32.4M | $61.8M | $62.6M | $55.6M | $53.9M | $48.7M | ||
| Research Expense | $32.4M | $61.8M | $62.6M | $55.6M | $53.9M | $48.7M | ||
| Selling, General & Administrative | $13.2M | $32.7M | $43.0M | $27.3M | $20.6M | $56.0M | ||
| General & Administrative Expenses | $13.2M | $32.7M | $43.0M | $27.3M | $20.6M | $56.0M | ||
| Salaries & Wages | $-6.2M | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | $-45.6M | $94.5M | $105.6M | $83.0M | -- | -- | ||
| OPERATING INCOME | ||||||||
| Operating income | $-45.6M | $-94.5M | $-105.6M | $-83.0M | $-64.5M | $-104.3M | ||
| EBITDA | $-45.5M | $-94.1M | $-105.2M | $-82.5M | $-117.3M | $-104.6M | ||
| NON-OPERATING ITEMS | ||||||||
| Intinc | $93.0K | $559.0K | $555.0K | $685.0K | $1.4M | $3.5M | ||
| Net Non-Operating Interest Income/Expense | $93.0K | $559.0K | $555.0K | $685.0K | $1.4M | $3.5M | ||
| Gain on Sale of Securities | $1.0K | $50.0K | -- | $16.0K | -- | -- | ||
| Other Income/Expense | $24.0K | $54.0K | $521.0K | $-243.0K | $56.6M | $4.9M | ||
| Other Special Charges | $-24.0K | $-54.0K | $-521.0K | $-243.0K | $-56.6M | $-4.9M | ||
| PRE-TAX INCOME | ||||||||
| EBIT | $-45.5M | $-94.5M | $-105.6M | $-83.0M | $-119.8M | $-105.6M | ||
| Pre-Tax Income | $-45.5M | $-94.0M | $-105.6M | $-82.5M | $-119.8M | $-105.6M | ||
| NET INCOME | ||||||||
| Net Income | $-45.5M | $-94.0M | $-105.6M | $-82.5M | $-119.8M | $-105.6M | ||
| Net Income (Continuing Operations) | $-45.5M | $-94.0M | $-105.6M | $-82.5M | $-119.8M | $-105.6M | ||
| Net Income (Discontinued Operations) | $-45.5M | $-94.0M | $-105.6M | $-82.5M | $-119.8M | $-105.6M | ||
| Net Income (Common Stockholders) | $-91.0M | $-94.0M | $-105.6M | $-82.5M | $-119.8M | $-105.6M | ||
| Normalized Income | -- | -- | -- | -- | -- | $-104.6M | ||
| TOTALS | ||||||||
| Total Expenses | $45.6M | $94.5M | $105.6M | $83.0M | $74.5M | $104.8M | ||
| SHARE & EPS DATA | ||||||||
| Average Shares Outstanding | $12.8M | $22.0M | $25.6M | $37.8M | $84.2M | $139.5M | ||
| Average Shares Outstanding (Diluted) | $12.8M | -- | $25.6M | $37.8M | $84.2M | $139.5M | ||
| Shares Outstanding | $22.0M | $26.0M | $26.2M | $48.1M | $105.9M | $141.6M | ||
| Basic EPS | -- | $-4.28 | $-4.12 | $-2.18 | $-1.42 | $-0.76 | ||
| Basic EPS (Continuing Operations) | -- | $-4.28 | $-4.12 | $-2.18 | $-1.42 | $-0.76 | ||
| Diluted EPS | $-3.55 | $-4.28 | $-4.12 | $-2.18 | $-1.42 | $-0.76 | ||
| Diluted EPS (Continuing Operations) | $-3.55 | -- | $-4.12 | $-2.18 | $-1.42 | $-0.76 | ||
| OTHER METRICS | ||||||||
| Accrued Preferred Stock Dividends | $45.5M | $94.0M | $105.6M | $82.5M | -- | -- | ||
| Other Gand A | $13.2M | $32.7M | $43.0M | $27.3M | $20.6M | $56.0M | ||
| Otherunder Preferred Stock Dividend | $45.5M | $94.0M | $105.6M | $82.5M | -- | -- | ||
| Preferred Stock Dividends | $45.5M | $94.0M | $105.6M | $82.5M | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | APLT | $0.48 | +9.5% | 1.41M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Applied Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW